Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Definium Therapeutics, Inc. (DFTX) had Return on Equity of -55.30% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-183.79M |
|
-- |
|
-- |
|
$166.31M |
|
$-166.31M |
|
$-17.48M |
|
$-183.79M |
|
$-183.79M |
|
$-183.79M |
|
$-183.79M |
|
$-183.79M |
|
$-183.79M |
|
$-166.31M |
|
$-168.13M |
|
89.33M |
|
89.33M |
|
$-2.06 |
|
$-2.06 |
|
| Balance Sheet Financials | |
$419.32M |
|
-- |
|
$20.78M |
|
$440.10M |
|
$66.70M |
|
$40.58M |
|
$41.08M |
|
$107.77M |
|
$332.33M |
|
$312.41M |
|
$332.33M |
|
98.78M |
|
| Cash Flow Statement Financials | |
$-131.56M |
|
$-151.61M |
|
$267.27M |
|
$273.74M |
|
$257.84M |
|
$-15.90M |
|
$20.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.29 |
|
-- |
|
-- |
|
0.11 |
|
0.12 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-131.56M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-55.30% |
-58.83% |
|
-41.76% |
|
-49.29% |
|
$3.36 |
|
$-1.47 |
|
$-1.47 |
|